Physician profile
Christina Biester
NPI 1891700506
$2,722.63
in general payments reported to CMS, 2019-2025
24 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $347 · 2021: $221 · 2022: $465 · 2023: $603 · 2024: $381 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.07 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $393.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.24 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $221.28 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Alkermes, INC. | $158.79 | 2019-2023 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $158.43 | 2019-2020 | |
| Amgen INC. | $125.95 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $103.04 | 2019-2023 | |
| Amarin Pharma, INC. | $72.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $72.29 | 2020-2024 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.81 | 2020-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $45.63 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $45.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.28 | 2019-2020 | |
| Corcept Therapeutics | $39.99 | 2024-2025 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $36.18 | 2023-2025 | Nuplazid |
| Stryker Corporation | $36.10 | 2025 | Clottriever Bold Catheter |
| Sanofi-Aventis U.S. LLC | $28.57 | 2022 | |
| Merck Sharp & Dohme LLC | $25.34 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.95 | 2025 | Caplyta |
| Hologic Sales and Service, LLC | $17.03 | 2023 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $16.19 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $13.33 | 2020 | |
| Pfizer INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Biester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.